- In patients with chronic HBV, tenofovir disoproxil fumarate (TDF) was associated with a lower incidence of hepatocellular carcinoma (HCC) than entecavir.
Why this matters
- The study includes a population-based cohort as well as a validation hospital cohort.
- Retrospective Korean study using nationwide (n=24,156; mean age, 48.9 years; 62.6% male) and hospital-based (n=2701; mean age, 48.8 years; 61.3% male) cohorts.
- Funding: Korean government.
- Nationwide sample (propensity-matched cohort, 10,923 pairs):
- Propensity-score analysis showed lower risk for HCC in the TDF group (HR, 0.62; P<.001>
- Risk for all-cause mortality or liver transplant was lower in the TDF group (HR, 0.79; P=.01).
- VR was worse in the entecavir group overall (78.7% vs 85.2%; P<.001 and in the propensity-matched cohort vs p>
- Propensity-score analysis adjusted for VR showed lower risk for HCC in the TDF group (HR, 0.68; P=.04).
- There was no significant difference in risk for all-cause mortality or liver transplant.
- Retrospective study.
- Korean population.